Jinlong Yin

Kaifeng, 475004, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 47 publications

Spatiotemporal-switchable 2D NIR-II single-atom nanozyme for single-cell-level surgical navigation and glioblastoma phototherapy.

Spatiotemporal-switchable 2D NIR-II single-atom nanozyme for single-cell-level surgical navigation and glioblastoma phototherapy.

Journal: Science translational medicine

Published: August 05, 2026

Disruption of the NDC80-Nek2 axis suppresses glioblastoma stemness and enhances therapeutic efficacy.

Disruption of the NDC80-Nek2 axis suppresses glioblastoma stemness and enhances therapeutic efficacy.

Journal: Journal of translational medicine

Published: July 20, 2025

Targeting MGAT4A-Mediated N-Glycosylation as a Therapeutic Strategy to Inhibit Glioblastoma Stem Cell Invasion.

Targeting MGAT4A-Mediated N-Glycosylation as a Therapeutic Strategy to Inhibit Glioblastoma Stem Cell Invasion.

Journal: Exploration (Beijing, China)

Published: April 09, 2025

Synapsin III promotes neuronal-like transdifferentiation of glioblastoma stem cells by disrupting JAG1-Notch1 interaction.

Synapsin III promotes neuronal-like transdifferentiation of glioblastoma stem cells by disrupting JAG1-Notch1 interaction.

Journal: Neuro-oncology

Published: February 24, 2025

Inhibition of ICAM1 diminishes stemness and enhances antitumor immunity in glioblastoma via β-catenin/PD-L1 signaling.

Inhibition of ICAM1 diminishes stemness and enhances antitumor immunity in glioblastoma via β-catenin/PD-L1 signaling.

Journal: Nature communications

Published: October 01, 2024

P4HB maintains Wnt-dependent stemness in glioblastoma stem cells as a precision therapeutic target and serum marker.

P4HB maintains Wnt-dependent stemness in glioblastoma stem cells as a precision therapeutic target and serum marker.

Journal: Oncogenesis

Published: August 13, 2024

MAGL targeted PROTAC degrader simultaneously enhances P53 for synergistic treatment of glioblastoma stem cell.

MAGL targeted PROTAC degrader simultaneously enhances P53 for synergistic treatment of glioblastoma stem cell.

Journal: Cell death discovery

Published: June 22, 2024

CD97 maintains tumorigenicity of glioblastoma stem cells via mTORC2 signaling and is targeted by CAR Th9 cells.

CD97 maintains tumorigenicity of glioblastoma stem cells via mTORC2 signaling and is targeted by CAR Th9 cells.

Journal: Cell reports. Medicine

Published: December 12, 2023

Single-cell dissection of the human blood-brain barrier and glioma blood-tumor barrier.

Single-cell dissection of the human blood-brain barrier and glioma blood-tumor barrier.

Journal: Neuron

Published: December 07, 2023

CREB5 promotes the proliferation and self-renewal ability of glioma stem cells.

CREB5 promotes the proliferation and self-renewal ability of glioma stem cells.

Journal: Cell death discovery

Published: April 16, 2023

Present Status and Advances in Chimeric Antigen Receptor T Cell Therapy for Glioblastoma.

Present Status and Advances in Chimeric Antigen Receptor T Cell Therapy for Glioblastoma.

Journal: Frontiers in bioscience (Landmark edition)

Published: February 25, 2023

Cross-talk between PARN and EGFR-STAT3 Signaling Facilitates Self-Renewal and Proliferation of Glioblastoma Stem Cells.

Cross-talk between PARN and EGFR-STAT3 Signaling Facilitates Self-Renewal and Proliferation of Glioblastoma Stem Cells.

Journal: Cancer research

Published: February 14, 2023

Showing 1-12 of 47

Last Updated: 09/26/2026